Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Smith & Nephew Snats ( (SNN) ) just unveiled an update.
On April 15, 2026, Smith & Nephew announced that Thérèse Esperdy, its Senior Independent Director designate, will join the board of Rentokil Initial as a Non-Executive Director and Chair-designate from July 1, 2026. She is scheduled to become Chair of Rentokil’s board on September 1, 2026, with the disclosure made in line with UK listing requirements.
The appointment underscores the prominence of Smith & Nephew’s board members within the wider UK corporate landscape and highlights growing cross-boardroom links between major FTSE-listed groups. While not altering Smith & Nephew’s own governance roles immediately, it signals Esperdy’s expanding influence and may enhance the company’s profile through increased visibility in another blue-chip UK company.
The most recent analyst rating on (SNN) stock is a Hold with a $35.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew is a global medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. Its 17,000 employees support three main business units—Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management—serving patients in more than 100 countries and generating $6.2 billion in sales in 2025.
Founded in Hull, UK, in 1856 and now headquartered in Watford, the FTSE 100 constituent is listed in London and New York and positions itself around the purpose of ‘Life Unlimited,’ using advanced technologies to improve patient outcomes worldwide.
Average Trading Volume: 866,856
Technical Sentiment Signal: Strong Buy
Current Market Cap: $14.38B
See more data about SNN stock on TipRanks’ Stock Analysis page.